微生物学
经典补体途径
肺炎链球菌
免疫系统
补体系统
单克隆抗体
脑膜炎奈瑟菌
免疫学
生物
病菌
抗体
铜绿假单胞菌
抗原
病毒学
肺炎
先天免疫系统
鲍曼不动杆菌
人类病原体
逃避(道德)
肺炎克雷伯菌
败血症
细菌性肺炎
补体受体
细菌
传染病(医学专业)
免疫
肺炎克雷伯菌
奈瑟菌
肺炎球菌感染
获得性免疫系统
替代补体途径
作者
Youssif Mohammed Ali,Munehisa Yabuki,Chanuka H Arachchilage,Priyanka Khatri,Nicholas J. Lynch,Sebastian Bruchmann,Aaron Weimann,Karen Brown,R. Andrés Floto,Julian Parkhill,Vidmantas Petraitis,Rūta Petraitienė,Thomas J Walsh,David E. Briles,Larry S. McDaniel,Heidi Utsugi,Galina Gragerova,Ayesha Misquith,Christiana Doulami,Gregory A. Demopulos
标识
DOI:10.1126/scitranslmed.adx4108
摘要
The expanding global crisis of bacterial infections caused by antimicrobial-resistant pathogens has resulted in an urgent need for therapeutics. Previous efforts to target pathogen surface antigens with monoclonal antibodies (mAbs) have sought to activate the complement system, primarily through the antibody-dependent classical pathway. However, most mAbs have induced insufficient complement activation because pathogen evasion strategies disrupt the complex spatiotemporal requirements for activation of the classical pathway initiation complex C1. To address this, we developed a targeted complement activation therapy (T-CAT), which uses antibodies furnished with the enzymatic capability to initiate complement activation directly on the bacterial surface without involvement of the classical pathway initiation complex. We found that T-CAT mAbs directed against bacterial surface antigens can overcome the strategies that pathogens evolved to escape from classical pathway–mediated clearance by the immune system. We further demonstrated that T-CAT mAbs could safely and effectively be used to treat infectious disease in experimental murine models of sepsis and pneumonia caused by Klebsiella pneumoniae , Pseudomonas aeruginosa , Streptococcus pneumoniae , and Neisseria meningitidis . Together, these data highlight the potential for T-CAT as a next-generation mAb platform with broad applicability against diverse microbial species, including multidrug-resistant pathogens, without promoting drug resistance.
科研通智能强力驱动
Strongly Powered by AbleSci AI